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ABSTRACT
Pregnancy in a patient diagnosed with systemic connective tissue disorder is a challenge that requires a close co-operation 
between a rheumatologist and gynaecologist. Good control over the activity of the underlying condition and the choice 
of appropriate time for planning a pregnancy have direct effect on the pregnancy results in these patients. Applying gy-
naecological supervision adequate to the increased risk of complications is also very important.
The aim of this study is to present the current knowledge on the care over pregnant patients with systemic connective 
tissue diseases and to draw attention to the importance of pregnancy planning in this group of patients.   
Key words: inflammatory rheumatic diseases; pregnancy; lupus erythematosus; adverse pregnancy outcomes
Ginekologia Polska 2021; 92, 9: 663–667
INTRODUCTION
Systemic autoimmune connective tissue diseases are 
a heterogeneous group of rheumatological conditions with 
common pathogenesis: autoimmune inflammation of the 
connective tissue. Depending on a disease, symptoms from 
many systems and organs determine various clinical mani-
festations.
According to the 1983 American Rheumatism Associa-
tion (ARA) classification of rheumatological diseases, sys-
temic connective tissue diseases include:
Systemic lupus erythematosus, rheumatoid arthritis, 
juvenile idiopathic arthritis, scleroderma, polymyositis, and 
dermatomyositis, vasculitis, Sjögren’s syndrome, overlap 
syndromes, including unspecified and mixed connective 
tissue disease, and others.
Typical age of diagnosis of systemic connective tissue 
diseases are typically found in patients between 20 and 
40 years old, i.e., in their reproductive age. Rheumatic diseas-
es, with rheumatoid arthritis being the most common one, 
are rare. Their prevalence is estimated at 0.001 to 1.0% [1].
The reason why connective tissue diseases affect women 
more often than men is unknown. Due to the rare occur-
rence of these disorders, resulting in limited experience in 
care over pregnant women with connective tissue diseases 
and the possible deterioration of mother and foetus con-
dition it seems that these patients should be treated at 
reference centres.
Based on the analysis of the course of pregnancy, and 
pregnancy outcomes of patients suffering from connec-
tive tissue disorders, pregnancy in this group of women is 
associated with a higher risk of complications and adverse 
pregnancy outcomes compared to the healthy population. 
The principal factors affecting the risk include organ com-
plications and high activity of the underlying disease [2, 3].
Effective symptom control due to proper pharmaco-
therapy, motivates patients to make a conscious decision 
to get pregnant.
The aim of this study is to present the current knowledge 
on the care over pregnant patients with systemic connective 
tissue diseases and to draw attention to the importance of 
pregnancy planning in this group of patients.
PREGNANCY MANAGEMENT
Preparation for getting pregnant
The time of becoming pregnant
Proper timing for trying to get pregnant in the case of 
patients with systemic connective tissue diseases is cru-
cial. It should be the time of low disease activity, obtained 
with pharmacotherapy that may be continued safely dur-
ing pregnancy [4]. The recommended period of symptom 
reduction, meeting the remission criteria, prior to getting 
pregnant differs between various diseases. In the case of 
lupus erythematosus, it is at least six months [5]. In patients 
diagnosed with other connective tissue diseases, without 
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extraarticular symptoms, three months of remission are 
deemed sufficient.
Pharmacotherapy
Another important element of preparation involves 
the analysis of medications used by the patient and the 
possibility of treatment continuation during pregnancy. 
The necessity to discontinue teratogenic drugs, if they are 
used to maintain remission, is associated with the risk of 
increased disease activity. Therefore, it is important that pa-
tients can continue their treatment and control the activity 
of the underlying disease also during pregnancy. Literature 
data demonstrate that in patients with systemic lupus ery-
thematosus using hydroxychloroquine discontinuation of 
the therapy is a significant risk factor for exacerbation of the 
underlying disease and adverse pregnancy outcomes [6–8]. 
Therefore, all pregnant patients with lupus should receive 
hydroxychloroquine, unless it is contraindicated.
The disease controlling drugs with known teratogenic 
effect that should be discontinued in advance before get-
ting pregnant include methotrexate - three months; cyclo-
phosphamide - three months; mycophenolate mofetil — 
six weeks [9–11].
 It is recommendable to discontinue the drugs that are 
contraindicated in pregnancy, whose effects on pregnancy 
have not been sufficiently studied, at least one month prior 
to the planned pregnancy. They include targeted synthetic 
disease-modifying antirheumatic drugs [9].
In the case of biologic drugs, their ability to penetrate 
the foetal circulation is varied; therefore, only some of them 
are approved for use in pregnancy [12].
Continuation of certain TNF inhibitors during pregnancy 
is acceptable, and the recommended time for their dis-
continuation before the planned delivery depends on the 
half-life of a given drug. This is to ensure that during the 
delivery the medication will not be present in the child’s 
organism, as it may be a risk factor for infections in the case 
of using live vaccines [13].
Organ dysfunction
Another step involves the assessment of organ dysfunc-
tion associated with the underlying disease. If the patient 
had a history of organ failure at any time, despite the sub-
sequent improvement or normalisation of the organ’s func-
tion, this fact significantly increases the risk of pregnancy 
complications, both foetal and maternal [14].
In the case of pulmonary hypertension, interstitial le-
sions in the lungs, heart failure, renal failure or multidrug-re-
sistant hypertension in a previous pregnancy, the decision 
regarding pregnancy should be taken by a multidisciplinary 
group of experts, due to the risk of increased pregnancy 
complications.
Presence of anti-SSA and anti-SSB antibodies
Another aspect to be considered when preparing for 
pregnancy is the assessment of anti-SSA and anti-SSB an-
tibodies. Anti- Sjögren’s syndrome-related antigen-A anti-
bodies (anti-SSA) /RO and anti-SSB/LA antibodies may be 
present not only in patients with Sjögren’s disease, but also 
with other systemic connective tissue diseases [15].
These antibodies actively penetrate the placental bar-
rier from approximately 16th week of gestation, which may 
cause atrioventricular blockage in the heart of the foetus, 
or neonatal lupus [16]. In most cases, heart blockage de-
velops between 18 and 24 weeks of gestation. The risk of 
complete heart blockage in the foetus of an SSA-positive or 
SSB-positive mother is two percent; however, it increases to 
18% if a blockage occurred already in a previous pregnancy 
[17]. Complete foetal heart blockage is the most dangerous 
complication, almost always requiring cardiac stimulation in 
the neonate, due to the irreversible changes in the electrical 
conduction system of the heart.
Determination of the anti-SSA or anti-SSB status of the 
mother already when planning pregnancy or in its early 
stage will enable proper supervision — ultrasound assess-
ment of the atrioventricular conductivity in the heart of 
the foetus.
If an early blockage is detected, therapy with steroids 
penetrating the placental barrier (dexamethasone, beta-
methasone) should be applied. [18]. However, the effective-
ness of this treatment was not clearly demonstrated.
The use of hydroxychloroquine was associated with 
a proven reduction of the rate of atrioventricular block in the 
foetuses of anti-SSA-positive and anti-SSB-positive mothers, 
as well as with decreased recurrence of this complication in 
subsequent pregnancies [19–21].
Skin, haematological and hepatic manifestations of neo-
natal lupus in most cases resolve after six to nine months 
following the birth, when maternal antibodies cease to 
circulate in the child’s organism [22].
Obstetric history
A detailed analysis of the previous obstetric history of 
the patient with systemic connective tissue disease is an es-
sential element of preparation for pregnancy. If the informa-
tion from the obstetric history reveals a negative pregnancy 
outcome, the cause should be established, and it should be 
determined whether it coincided with exacerbation of the 
underlying disease. The patient should be informed that 
proper preparation for pregnancy and appropriate period 
of symptom remission increase the chances of successful 
pregnancy outcome.
Negative pregnancy outcomes that meet one of the 
clinical criteria of antiphospholipid syndrome (APS) require 
verification of this diagnosis in laboratory tests before the 
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patient gets pregnant again. Patient’s blood serum should 
be tested for antiphospholipid antibodies (anticardiolipin 
antibody, beta-glycoprotein 1 antibody and lupus antico-
agulant). The diagnosis of antiphospholipid syndrome must 
be supported by two positive results for at least one of 
three antibodies at medium or high titres, performed at 
least 12 weeks apart, together with a clinical criterion [23].
Presence of anticardiolipin antibody doubles the risk of 
venous thrombosis in patients with systemic lupus. The risk 
is six times higher in patients with positive test results for 
lupus anticoagulant, compared to lupus patients without 
these antibodies [24]. In patients with antiphospholipid 
syndrome, anticoagulatory prevention with low-molecu-
lar-weight heparin is recommended throughout the preg-
nancy and the postpartum period is recommended.
In the context of anti-SSA/anti-SSB antibodies, it is al-
ways necessary to ask patients about the occurrence of 
atrioventricular blockage or neonatal lupus in their children.
The effect of the underlying disease on the course of 
pregnancy
Due to a limited prevalence of connective tissue dis-
eases, their effect on the course of pregnancy has been 
studied most extensively in the population of patient with 
the most common disorders within this group: lupus and 
rheumatoid arthritis. Other connective tissue diseases also 
increase the risk of pregnancy complications, especially 
when the activity of the disease is high, antibodies are pre-
sent, or organ complications occur.
The data from retrospective studies indicate that in pa-
tients with RA pregnancy complications, i.e., pregnancy-in-
duced hypertension, pre-eclampsia, FGR and premature 
birth occur significantly more often than in the healthy 
population of pregnant women. These pregnancies also re-
quired Caesarean section delivery more frequently [25–27].
A meta-analysis of studies from the years 2001–2016, 
including 3,395 patients with lupus demonstrated nearly 
a double increase of the relative risk (RR) of pregnancy-in-
duced hypertension and pre-eclampsia, over three times 
higher risk or premature birth, and over four times higher 
risk of growth retardation in the child [28].
Pregnancy supervision
Care over a patient with a systemic connective tissue 
disease should be provided by a multidisciplinary team, 
including a rheumatologist, obstetrician and, depending on 
the organ complications specific for the patient, specialists 
in other fields of medicine.
For a patient with a connective tissue disease preg-
nancy is a special time, and it requires a regular monitor-
ing of disease activity. Systematic control of the disease 
activity markers conducted by the patient’s rheumatologist 
will enable early detection of exacerbations, and potential 
modification of pharmacotherapy. According to the pres-
ence of risk factors, determined before the conception, 
the supervision over the patient must be individualised. 
In addition to the gynaecological examination and blood 
pressure tests performed at every visit, laboratory studies 
should be performed to assess renal function (creatinine, 
general urinalysis, presence of protein in urine), liver func-
tion (AlAT, AspAT), and complete blood count. If arterial 
hypertension occurs, it should be controlled regularly, both 
by Holter and home blood pressure monitoring to optimise 
pharmacology treatment.
All pregnant patient with a systemic connective tissue 
disease, especially lupus erythematosus, are at high risk 
of pre-eclampsia, so preventive treatment with low doses 
of acetylsalicylic acid (≤ 150 mg) is recommended [5, 29]. 
The suggested time for initiation of the prophylactic therapy 
is 12–16 weeks of pregnancy.
The factors additionally increasing the risk of pre-ec-
lampsia in patients with lupus include active disease at six 
months prior to conception, lupus nephritis, chronic hyper-
tension, presence of antiphospholipid antibodies, low levels 
of complement components and thrombocytopaenia [30]. 
Doppler ultrasound examination of the flow in the uterine 
arteries in the second trimester is also recommended. Pres-
ence of bilateral early diastolic notches in these arteries 
between 23 and 25 weeks of gestation is a predictive factor 
for pre-eclampsia and pregnancy hypertension [31].
Differentiation between pre-eclampsia and lupus ne-
phritis poses a significant challenge in the management 
of patients with lupus. In both cases, the clinical manifes-
tation may include proteinuria, oedema, impaired renal 
function, hypertension and thrombocytopaenia. Lupus 
nephritis is characterised by reduced concentrations of 
complement components C3 and C4, increased titres 
of anti-dsDNA antibodies, active urinary sediment (pres-
ence of dysmorphic erythrocytes, erythrocyte casts and 
granular casts), and manifestation of other dermatologi-
cal, articular and haematological symptoms of disease 
exacerbation. In pre-eclampsia, the levels of complement 
components C3 and C4 typically increases [32]. If the two 
conditions cannot be differentiated clinically, a kidney bi-
opsy may be required. The only effective management in 
the case of intensified symptoms posing a threat to the lives 
of the mother or the child due to severe pre-eclampsia is 
premature delivery of the child, which may also be neces-
sary to administer proper immunosuppressants for exac-
erbated nephritis.
In patients diagnosed with antiphospholipid syndrome, 
anticoagulatory prevention during pregnancy with low-mo-
lecular-weight heparin is recommended [33]. These preg-
nant patients, and women with other rheumatic diseases, 
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especially with systemic lupus, should receive antiplatelet 
therapy with low doses of aspirin.
In patients positive for anti-SSA and anti-SSB antibodies 
ultrasound monitoring of the atrioventricular conduction 
time in the foetus is required. The conduction time can be 
measured in an ultrasound examination using the M-mode 
technique, pulsed Doppler and tissue Doppler. Normal atrio-
ventricular conduction time in a foetus is 110–150 ms [34]. 
Following the recommendations of the American Heart 
Association, monitoring of the foetus of a patient positive 
for anti-SSA or anti-SSB antibodies should start at 16 weeks 
of gestation. Measurements should be performed weekly, 
until 24 weeks of gestation.
SUMMARY
Despite pregnant women diagnosed with inflammatory 
rheumatic diseases are in the group of greater risk of adverse 
pregnancy outcomes, following up to date principles of 
pregnancy planning and supervision can rise the chance 
of motherhood of those patients.  
Due to the risk of disease exacerbation and sudden 
deterioration of both mother and feats condition those 
patients require multidisciplinary monitoring and should 
be referred to reference centre in case of the necessity of 
advance obstetric and neonatal care.
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